

RECEIVED #12
FEB 15 2002

TECH CENTER 1600/2900
Patent

Attorney's Docket No. 010830-117

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE



Inventor Patent Application of
Jozsef MASTERNAK et al.

Application No.: 09/840,243

Filing Date: April 24, 2001

For: NEW TRANSCRIPTION FACTOR
OF MHC CLASS II GENES, SUB-
STANCES CAPABLE OF INHIBITING)
THIS NEW TRANSCRIPTION)
FACTOR AND MEDICAL USES)
OF THESE SUBSTANCES)

) Group Art Unit: 1623

) Examiner: Unassigned

**RESPONSE TO NOTICE TO COMPLY WITH SEQUENCE LISTING
REQUIREMENTS AND PRELIMINARY AMENDMENT**

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

In complete response to the Notice to Comply with Requirements for Patent
Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures
mailed on December 13, 2001 and prior to examination on the merits, please amend the
above-identified application as follows:

IN THE SPECIFICATION:

Kindly replace the paragraph beginning at page 62, line 31 with the following:

--In vitro transcription-translation reactions and electrophoretic mobility shift assays
(EMSA) using nuclear extracts and in vitro translated proteins were done as described^{9,22,50}.

09840243.021302